InnoTherapy (246960) Stock Overview

InnoTherapy, Inc., engages in the development and sale of medical sealant products in South Korea. The company's products include InnoSEAL, an externally applied hemostatic agent; InnoSEAL Plus, an absorbable hemostatic pad; EndoSil, an absorbable hemostatic agent used for the gastrointestinal oozing bleeding; GellySil, a biomaterial and the proprietary material product. It also provides Film-type surgical sealant to complete sealing of anastomosis site; STOP needle, a self-sealing needle for general and ophthalmic use; wound dressing used for chronic wounds, burns, etc.; and Gene therapy, a bio-therapeutics delivery system. The company was founded in 2010 and is headquartered in Seoul, South Korea.